Press release: Uppsala, October 19, 2020. Dicot AB ("Dicot" or the "Company") announce the outcome regarding exercising of warrants of series TO1 2019 for the subscription of new shares. In total, 2,894,950 warrants were exercised, corresponding to approximately 37.2 percent of the total number of warrants of series TO1 2019 issued, for the subscription of 5,326,701 shares at a price of SEK 1.42 per shares. Through the subscription of shares using warrants Dicot will receive approximately 7.6 MSEK, before issuing costs.
During the third quarter of 2019 Dicot carried out a right's issue of units, consisting of 1 share and 1 warrant, free of charge, of series TO1 2019. The subscription period for the warrants lasted from October 1 up until October 15, 2020. After the adjustment of the warrants of series TO1 2019 that was communicated on September 29, in accordance with the terms for the warrants regarding subscription price and amount of shares that one warrant entitled the owner to, the subscription price for new shares through exercising of warrants was set to SEK 1.42 per share.
Exercised warrants have been replaced with interim shares (IS) until the issue has been registered at the Swedish Companies Registration Office. The interim shares will be transformed into ordinary shares within approximately 3 weeks.
Complete terms for the warrants are available on the Company's website: https://www.dicot.se/investerare-media/teckningsoptioner-20192020/.
Number of shares and share capital
Through the exercising of the warrants the number of shares of Dicot is increased with 5,326,701 shares, from 38,341,697 to 43,668,398 shares. The share capital is increased by SEK 665,857.625, from SEK 4,792,712 to SEK 5,458,549.75.
For the existing shareholders that did not exercise any warrants of series TO1 2019 the dilution amounts to approximately 12.2 percent.
Mangold Fondkommission is the financial adviser, and Advokatfirman Lindahl is the legal adviser, for Dicot regarding the warrants.
For questions regarding the warrants, please contact:
Mangold Fondkommission AB
Tel: +46 8 5030 1595
For additional information, please contact:
Göran Beijer, CEO
Tel: +46 70-663 60 09
Dicot AB in brief
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The Company's lead drug candidate, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 1,600 shareholders. For more information see www.dicot.se.
This information is such that Dicot AB is required to make public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on October 19, 2020.